What Lemtrada Treats: Main Uses and Benefits

Lemtrada is commonly used in adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS (RRMS) and active secondary progressive MS, particularly in highly active disease. This medicine is relevant in contexts involving heightened systemic burden and helps address the burden of recurrent neurological relapses and the underlying active inflammation seen on imaging. A recognized patient-oriented benefit is a reduction in the annualized relapse rate, which helps patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.

For this reason, this medicine is commonly used for adults who have demonstrated an inadequate response to at least two other disease-modifying therapies. The therapy plays a role in managing the risk of long-term physical disability accumulation—symptoms that interfere with daily functioning—and may assist with the potential for sustained improvement in existing deficits, supporting better long-term functional capability. For patients with persistent disease activity, this therapeutic approach supports long-term disease management and the stabilization of neurological function.

Quick Fact: Support for Relapsing MS
Therapeutic Focus	Supports long-term disease management.
Symptom Focus	Recurrent relapses and accumulation of disability.
Context	Applied when two or more prior treatments have failed.
Benefit	Assists with maintaining functional stability.

The eligibility for Lemtrada (alemtuzumab) is strictly defined by regulatory agencies. Its use is generally reserved for adult patients with relapsing forms of multiple sclerosis who have demonstrated an inadequate response to two or more prior disease-modifying therapies (DMTs).

Population Group	Eligibility Status
Allowed Population	Adults (18+ years) with specific disease activity and prior treatment failure.
Use Not Recommended	Patients under 18 years of age (safety not established); patients with severe renal or hepatic impairment (unstudied); those with inactive disease.
Contraindicated Groups	HIV infection; known hypersensitivity to the medicine; presence of a severe active infection; specific cardiovascular disorders (e.g., history of stroke, uncontrolled hypertension); known coagulopathy; other concomitant autoimmune diseases besides MS.

Age and Organ Function: Use in the pediatric population (under 18) is officially not recommended due to lack of established data. Use in patients with severe renal or hepatic impairment is also not recommended as these groups have not been studied in trials.

Pregnancy and Lactation: Use of this medicine is formally contraindicated during pregnancy. Females of childbearing potential must use effective contraception during treatment and for four months following the last infusion. Breastfeeding must also be discontinued for four months after the final infusion of each course.

Interactions with other medicines and products

Official regulatory information for Lemtrada (Alemtuzumab) interactions is primarily based on the drug’s profound effects on the immune system, leading to specific restrictions on co-administered products.

Interaction Scope

Property	Official Regulatory Statement
Medicinal product categories with documented interactions	Live, attenuated vaccines; Other immunosuppressive or immunomodulatory agents.
Mechanistic basis of interactions	Pharmacodynamic: Immune suppression and prolonged lymphopenia (lymphocyte depletion) leads to the risk of severe infection or vaccine-induced disease with live viral vaccines. Pharmacokinetic: No formal drug interaction studies have been performed regarding the CYP enzyme system or transporters.
Timing-based interaction rules	Live viral vaccines must not be administered following a course of Lemtrada. Immunizations must be completed at least six weeks prior to the initiation of treatment.
Interaction-related restrictions	Prohibited Co-administration: Live viral vaccines. Food Restriction: Patients must avoid foods that may be a source of Listeria monocytogenes due to the documented increase in listeriosis risk.

Resulting Interaction Structure

The regulatory labels specify that the co-administration of live, attenuated vaccines is contraindicated, given the documented risk of severe or fatal infection due to the drug's effects on circulating immune cells. Use of other immunosuppressive therapies is generally restricted or approached with caution due to the potential for additive immune suppression. Furthermore, the official labeling mandates a food safety restriction advising avoidance of Listeria-risk foods, and requires that all necessary pre-treatment immunizations be completed at least six weeks prior to drug initiation. The overall interaction profile is defined by these pharmacodynamic constraints, as no pharmacokinetic interactions involving CYP enzymes or transporters are formally documented.

Targeted Lymphocyte Depletion

This domain covers the initial molecular action of the drug. Lemtrada is a monoclonal antibody that binds to the CD52 glycoprotein found on the surface of mature T and B lymphocytes. This binding acts as a tag, initiating their rapid destruction through immune mechanisms like Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), resulting in profound, transient lymphopenia. This massive cellular depletion results in a period of profound lymphopenia, which alters the balance of circulating immune mediators.

---

Immune System Repopulation and Reset

This domain describes the resulting mechanistic cascade and functional change. Because the drug does not target immune stem cells, the immune system begins a slow process of reconstitution. The new lymphocytes that emerge often show a different profile, with an enriched proportion of regulatory T cells (Tregs). This modification of the immune cell repertoire establishes a new immunological profile characterized by an altered ratio of regulatory and effector cells within the targeted pathways.

Lemtrada (alemtuzumab) is administered as an intravenous (IV) infusion for the treatment of relapsing forms of multiple sclerosis, generally reserved for patients who have had an inadequate response to two or more other MS therapies. Due to the risk of serious side effects, the medicine is only available through a restricted distribution program, which ensures patient and provider education on ongoing monitoring requirements.

Dosing Schedule

The full course of treatment involves two separate courses, spaced approximately 12 months apart, with an individual dose of 12 mg per day. The infusion is typically administered over about four hours in a healthcare facility equipped to manage serious infusion reactions.

Treatment Course	Daily Dosage	Duration	Interval
First Course	12 mg	5 consecutive days	Initial administration
Second Course	12 mg	3 consecutive days	12 months after first course

Subsequent treatment courses of 12 mg daily for 3 consecutive days may be administered as needed, but no sooner than 12 months after the previous course.

Required Monitoring and Pretreatment

To manage potential risks like infusion reactions and autoimmunity, patients must be pre-treated with corticosteroids immediately before the infusion on the first three days of each course. Antiviral prophylaxis for herpes infection is also required, starting on the first day of treatment and continuing for a minimum of one to two months after the final dose of each course.

Ongoing laboratory monitoring, including complete blood counts, serum creatinine, and urinalysis, is mandatory before starting treatment and must continue at monthly intervals until at least 48 months after the final infusion of the last course.

Research Evidence / Overview of Studies for Lemtrada

Clinical Evidence for Relapsing Multiple Sclerosis (RMS)

The research into this medicine has primarily involved Randomized Controlled Trials (RCTs), which are a comparative study design often used for evaluating medicines. These studies examined the measured differences between the study medicine and an active comparator (Interferon beta-1a) in adults with Relapsing Multiple Sclerosis (RMS), a condition characterized by fluctuating or episodic manifestations. Researchers carefully monitored key outcomes related to episodic or acute changes in disease activity and outcomes reflecting daily functioning or activity level.

• Studies in Treatment-Naïve Patients

  This sub-section focuses on trials that were evaluated in adult patients who had not received prior disease-modifying therapies for MS. Research explored how often participants experienced relapses and whether they developed new signs of disease activity, such as new lesions visible on MRI. In these studies, findings describe patterns observed where studies noted differences in the measured relapse rate between the study medicine group and the active comparator group. When examining sustained accumulation of disability (a long-term measure of functional worsening), the initial trials studies reported no statistically significant difference in this outcome between the two groups over the two-year observation period.

• Studies in Treatment-Experienced Patients

  This sub-section will outline research conducted in patients who were experiencing active disease, having had relapses despite previously receiving other MS treatments. These studies monitored the same key clinical and radiological outcomes. Studies reported patterns related to the annualized relapse rate compared to the comparator. Furthermore, in this specific population, the research described different patterns of confirmed disability accumulation between the study medicine group and the comparator group over the two-year study period.

Long-Term Research and Durability of Follow-Up

Due to the nature of this medicine, researchers conducted open-label extension studies to monitor patients for many years after they completed the initial two-year trials, even if they did not receive additional courses of the study medicine. This section describes the extended follow-up period, which has tracked some participants for up to seven to nine years, and in some cases, up to 12 years.

This extensive research was observed in these large cohorts to observe the long-term patterns related to disease activity. Many patients who participated in these studies did not receive additional courses of the study medicine during the extended follow-up period. Findings describe patterns observed where the measured relapse rates were observed in the study populations over the years following treatment, and patterns were described related to the proportion of patients without confirmed disability worsening. The long-term studies also continued to monitor radiological activity, with research explored how outcomes evolved and how disease activity appeared on MRI over these defined time intervals.

Common questions about Lemtrada (FAQ)

---

Q: What are the long-term effects of taking Lemtrada?

Regulatory documents include information on potential long-term risks. These risks involve the development of serious, delayed autoimmune conditions that can occur months or years after treatment, such as Immune Thrombocytopenic Purpura, kidney damage, or thyroid disorders. Official product information also notes an increased risk of certain malignancies like thyroid cancer and melanoma.

---

Q: Why is Lemtrada administered in separate treatment courses?

The approved dosing schedule involves an initial treatment course followed by a second course 12 months later. This is related to the drug's mechanism, which causes a rapid depletion of certain immune cells (lymphocytes) followed by a slow, long-term reconstitution of the immune system. Subsequent courses may be administered only as needed and no sooner than 12 months after the prior course.

---

Q: What kinds of infections should patients watch out for?

Official labeling states there is a risk of serious infections, including fatal infections. Official information identifies signs of serious infection, particularly those caused by herpes viruses, Progressive Multifocal Leukoencephalopathy (PML), and Listeria infection. Due to this risk, an antiviral medication is prescribed alongside treatment.

---

Q: Is there a maximum number of treatment courses a person can receive?

The approved treatment schedule involves an initial two courses. Following the second course, the official documents state that subsequent treatment courses may be administered as needed. There must be a minimum interval of 12 months between any treatment courses.

---

Q: Does Lemtrada affect fertility or make it harder to become pregnant?

It is not known whether this medicine affects human fertility. However, animal studies have indicated that the drug may cause adverse effects on male reproductive organs. For women of childbearing potential, official guidance specifies that they are required to use effective contraception during and for at least four months after each treatment course.

---

Q: What is the experience of the actual infusion process like?

The infusion is administered over a period of approximately four hours. The procedure includes the administration of corticosteroid medication before the infusion to help reduce the chance of infusion-related reactions. Patients must also be monitored by a healthcare professional for at least two hours following each infusion.

---

Q: Can a person with a history of certain cancers use Lemtrada?

The medication is contraindicated in patients who have active second malignancies.

---

Q: Are there different restrictions for men and women using Lemtrada?

Yes. Official guidance specifies that women of childbearing potential are required to use effective contraception during treatment and for four months following the last infusion. Additionally, animal data showed effects on male reproductive organs.

---

Q: What type of pre-screening tests are required before starting Lemtrada?

Official labeling describes several screening tests that are necessary before the first dose is administered. These tests include screening for Human Immunodeficiency Virus (HIV), Hepatitis B and C virus, and a tuberculosis (TB) screening test.

---

Q: Can Lemtrada affect liver function, and how is this monitored?

The official label notes that the medicine can cause serious liver injury, including Autoimmune Hepatitis. Official monitoring requirements indicate that Liver function tests (ALT and AST) are necessary before and periodically throughout the treatment period.

---

Q: What are the typical expected outcomes described in the clinical research?

Clinical studies examined the drug and described measured differences in the annualized relapse rate when compared to an active comparator. Studies also showed a different pattern of confirmed disability accumulation in patients treated with the medicine.

---

Q: Does the treatment require any special preparation at home?

Yes. Official documentation specifies that antiviral prophylaxis (a preventive medication) is necessary to guard against herpes infection. This medication must be started on the first day of treatment and continued for a minimum of one to two months after the final dose of each course.

---

Q: How quickly does Lemtrada start working after the infusion?

The initial action of the drug involves a rapid depletion of lymphocytes (a type of white blood cell). Clinical research indicates that differences in the annualized relapse rate were observed in studies starting in the first year of observation.

---

Q: Can Lemtrada cause hair loss or changes in skin?

Official labeling lists dermatological adverse reactions. Rash is reported in regulatory documents as a very common adverse reaction. Alopecia (hair loss) is also listed as a common adverse reaction that can occur.

---

Q: What are the signs of a thyroid problem related to Lemtrada?

Thyroid gland disorders are a potential risk. These include both hyperthyroidism (overactive) and hypothyroidism (underactive). Signs of a potential thyroid issue can include a racing heart, increased sweating, fatigue, or unexplained weight gain or loss.

---

Q: Can I drive a car immediately after receiving the infusion?

Official safety information states that the medicine can have a minor influence on the ability to drive or use machines. This is because potential adverse effects, such as dizziness or fatigue, may occur following the infusion.

---

Q: How long after stopping Lemtrada does it stay in the body?

The half-life of the active substance in the body is approximately four days. The substance is typically undetectable in the blood within 30 days after a treatment course is completed.

---

Q: Are there common emotional or mood changes reported with Lemtrada?

Clinical data reported in regulatory documents lists depression as a common adverse reaction, meaning it was observed in at least 1% but less than 10% of patients in studies.

---

Q: What is the difference between an infusion-associated reaction and a side effect?

The official product information makes a distinction between these events. Infusion-related reactions are reactions that typically occur during or within 24 hours of administration. Other adverse reactions (side effects) include serious events like autoimmune conditions and thyroid disorders that may have a delayed onset of months or years after treatment.

How to Store and Dispose of Lemtrada (alemtuzumab)

Official labeling defines strict storage and handling requirements for Lemtrada to maintain product integrity.

Storage Requirements

Storage Component	Official Requirement
Temperature (Undiluted)	Must be refrigerated at 2 C to 8 C (36 F to 46 F).
Prohibited Conditions	Do not freeze the vials and do not shake them before use.
Light Protection	Keep the unopened vial in its original outer carton to protect from light.
Child Safety	Store the product out of the sight and reach of children.

Stability and Disposal

Once diluted for infusion, the solution has a maximum stability limit and must be administered starting within 8 hours of preparation. The prepared solution must also be protected from light during this time. The Lemtrada vial is for single use only. Any unused or remaining product in the vial must be discarded according to local requirements for pharmaceutical waste.